HomeNewsBusinessH-1B visa ban may not make that big a dent in top IT firms' revenues. Here's why

H-1B visa ban may not make that big a dent in top IT firms' revenues. Here's why

Top Indian IT firms' H-1B dependency has come down by 40-60 percent since 2017.

June 23, 2020 / 20:05 IST
Story continues below Advertisement

Top Indian IT firms have reduced their US visa dependency by 40-60 percent since President Donald Trump took office in 2017. In other words, the latest move by the American government to ban non-immigrant visas such as H-1B and L-1 may not make as big a dent as feared.

Share of Infosys in the H-1B pie fell the most, down 60 percent from 14,586 visas in FY17 to 5,496 in FY20. This is followed by Wipro at 56 percent, TCS at 52 percent and HCL Tech at 46 percent. For Cognizant, the drop in H-1B visas was 56 percent in FY19 compared to FY17.

Story continues below Advertisement

This drop came on the back of increased denials and request for evidences due to stringent visa regulations in the US.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show